ROMA值对卵巢癌发病风险预测的价值

The value of combined HE4 and CA125 assays in prediction for the risk of ovarian cancer

目的探讨血清人附睾分泌蛋白4(HE4)和CA125联合检测及卵巢恶性肿瘤风险算法(ROMA)值对卵巢癌发病风险预测的价值。方法用化学发光法检测212例已确诊为卵巢癌的患者(卵巢癌组)、284例确诊为卵巢良性肿瘤的患者(卵巢良性肿瘤组)血清HE4和CA125水平,计算ROMA值并对结果进行比较分析。将未绝经者和绝经者ROMA值分别大于7.4%和25.3%判断为卵巢癌发病高风险。结果未绝经患者的敏感度和特异度分别为82.86%和75.83%;绝经患者的敏感度和特异度分别为88.89%和77.27%。高风险患者在卵巢癌中所占比例明显高于卵巢良性肿瘤组(P<0.05)。结论联合检测血清HE4和CA125水平并计算ROMA值可用于对卵巢癌发病风险的预测。

Objective To investigate the value of combined serum HE4 and CA125 assays and calculate the ROMA in prediction for the risk of ovarian cancer.Methods Chemiluminescence was used to measure the serum HE-4 and CA125 levels of 212 patients with ovarian cancer（ovarian cancer group） and 284 patients with ovary benign disease（benign ovarian tumor group）,then ROMA value was calculate and analysed.The premenopausal and menopausal women were judged to be high-risk for ovarian cancer when their ROMA values were greater than 7.4% and 25.3% respectively.Results The sensitivity and specificity of ROMA values for ovarian cancer risk assessment were 82.86% and 75.83% in premenopausal women,while 88.89% and 77.27% in menopausal women.The proportion of high-risk patients in ovarian cancer group was significantly higher than that in benign ovarian tumor group（P＆lt;0.05）.Conclusion The combined serum CA125 and HE4 levels measurements and ROMA values can be used for predicting the risk of ovarian cancer.